India’s Aurobindo looks to buy Novartis generic derma biz

May 07, 2018

Hyderabad-based Aurobindo Pharma has entered the race to buy Novartis' generics dermatology business for about $1.6 billion.

If the acquisition is successful, it will be the biggest overseas acquisition by any Indian drug major since Lupin's acquisition of Gavis Pharma and Novel Laboratories for $880 million in 2015.

So far, Aurobindo is only Indian drug company interested in the acquisition.

Media sources say Aurobindo had submitted an initial bid to buy Sandoz' dermatology assets, which includes dermatology brands, production facilities and other, primarily U.S.-based  infrastructure.

Read the India Info Online coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments